Ardena has officially completed the divestment of its drug substance manufacturing site in Sweden to Nanologica, marking a significant strategic move in the contract pharmaceutical sector. The transaction reinforces Nanologica’s position in advanced drug development and manufacturing, while allowing Ardena to streamline its operations and focus on its core competencies. This deal highlights ongoing consolidation trends within the pharmaceutical contract services industry as companies aim to optimize their portfolios and capabilities.
Ardena Finalizes Sale of Sweden Drug Substance Site to Nanologica
Ardena has officially completed the divestment of its drug substance manufacturing facility located in Sweden to Nanologica, marking a significant shift in its operational focus. This strategic move allows Ardena to concentrate more deeply on its core competencies in drug development and analytical services, while Nanologica plans to expand its footprint in the pharmaceutical…
—-
Author : Sophia Davis
Publish date : 2026-02-02 17:39:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
